J Korean Med Sci.  2011 Jul;26(7):954-958. 10.3346/jkms.2011.26.7.954.

Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib

• Jeong HK
• Roh SY
• Hong SH
• Won HS
• Jeon EK
• Shin OR
• Lee SL
• Ko YH

• KMID: 1094270
• DOI: http://doi.org/10.3346/jkms.2011.26.7.954

Abstract

A 31-yr-old man with abdominal pain was diagnosed with a pancreatic endocrine tumor and multiple hepatic metastases. Despite optimal treatment with interferon alpha, a somatostatin analog, local therapy with high-intensity focused ultrasound ablation for multiple hepatic metastases, and multiple lines of chemotherapy with etoposide/cisplatin combination chemotherapy and gemcitabine monotherapy, the tumor progressed. As few chemotherapeutic options were available for him, sorafenib (800 mg/day, daily) was administered as a salvage regimen. Sorafenib was continued despite two episodes of grade 3 skin toxicity; it delayed tumor progression compared to the previous immunotherapy and chemotherapy. Serial computed tomography scans showed that the primary and metastatic tumors were stable. Thirteen months after beginning targeted therapy, and up to the time of this report, the patient is well without disease progression. We suggest that sorafenib is effective against pancreatic endocrine tumors.

Keyword

Neuroendocrine Tumors; Chemotherapy; Sorafenib

MeSH Terms

Adult
Antineoplastic Agents/adverse effects/*therapeutic use
Benzenesulfonates/adverse effects/*therapeutic use
Humans
Liver Neoplasms/drug therapy/pathology/secondary
Male
Neuroendocrine Tumors/*diagnosis/drug therapy/pathology
Pancreatic Neoplasms/*diagnosis/drug therapy/pathology
Pyridines/adverse effects/*therapeutic use
Salvage Therapy
Skin Diseases/chemically induced
Tomography, X-Ray Computed

Figure

• 

  Fig. 1 Radiologic images of pancreatic, non-functioning, well-differentiated, endocrine carcinoma and multiple liver metastases. (A) Contrast enhanced CT scan (02/19/2009) shows a 6.8 cm lobulated mass in the uncinated process of the pancreas (arrow). The tumor shows focal cystic and necrotic areas, and heterogeneous enhancement. Multiple hematogenous metastases are also noted (arrowheads). (B) Follow-up contrast enhanced CT scan (03/31/2009) shows the lobulated mass in the uncinated process measuring 5.4 cm in maximal diameter. A comparison with the previous CT scan (A) reveals interval partial regression of the primary tumor mass in the uncinate process (arrow) and hematogenous hepatic metastases (arrowheads).

• 

  Fig. 2 Pathologic findings of the pancreatic, non-functioning, well-differentiated, endocrine carcinoma. (A) Histologic examination shows that the tumor cells were arranged in trabeculae and solid nests separated by a fibrous or loose fibrovascular stroma (H&E, × 100). (B) All tumor cells were large and polygonal in shape and had abundant, eosinophilic, and finely granular cytoplasm containing round to oval nuclei with finely stippled chromatin (H&E, × 400). (C) Tumor cells were strongly positive for chromogranin (IHC, × 400).

Reference

1. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008. 34:324–332.

2. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002. 20:2633–2642.

3. Costa F, Domenichini E, Garavito G, Medrano R, Mendez G, O'Connor J, Rojas W, Torres S, Younes RN, Delle Fave G, Oberg K. Management of neuroendocrine tumors: a meeting of experts from Latin America. Neuroendocrinology. 2008. 88:235–242.

4. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008. 103:475–483.

5. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005. 128:1668–1684.

6. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E. The "normal" endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci. 2004. 1014:1–12.

7. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology. 2009. 89:217–222.

8. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009. 38:255–258.

9. Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM. CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol. 2007. 62:371–377.

10. Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B, Skogseid B, Akerström G. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg. 2000. 24:1353–1360.

11. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004. 27:485–488.

12. Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer. 2003. 89:1766–1775.

13. Borre M, Nerstrøm B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 2000. 6:1882–1890.

14. Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer. 2006. 13:135–149.

15. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol. 2002. 10:139–146.

16. Carr K, Yao JC, Rashid A, Yeung S-C, Szklaruk J, Baker J, Vaugthey JN, Curley S, Ellis L, Afani JA. A phase II trial of imatinib in patients with advanced carcinoid tumor. J Clin Oncol. 2004. 22:4124.

17. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008. 26:3403–3410.

18. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010. 28:69–76.

19. Karhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch DK, Hörsch D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007. 85:45–53.

20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004. 64:7099–7109.